Annexins in human breast cancer: Possible predictors of pathological response to neoadjuvant chemotherapy
Introduction
Neoadjuvant chemotherapy (NAC) is being used increasingly in women with breast cancer, particularly in those who have large [(L) 3–5 cm] or locally advanced [(LA) T3, T4, N2] breast cancers (BCs).1 The advantages of NAC are to downstage the BCs, thereby, increasing the likelihood of breast conserving surgery (up to 50%) and reducing systemic micrometastatic tumour load, and thus possibly improving long-term survival.2, 3 Moreover, NAC can provide an opportunity to assess the likely outcome in any subsequent adjuvant therapeutic setting.4 NAC treatment with 4 cycles of adriamycin and cyclophosphamide, followed subsequently by 4 cycles of docetaxel, has demonstrated a good overall clinical response (up to 90%).4 However, the complete pathological response (cPR) rate is far less (up to 30%).4, 5, 6 NAC is a toxic and expensive treatment. Therefore, it would be clinically very beneficial to patients and satisfying to medical personnel if it was possible to predict the likelihood of response to NAC, thereby, selectively targeting treatment to those likely to benefit and preventing those patients unlikely to respond from undergoing expensive, toxic, prolonged and unnecessary treatment. However, to date, there is no study that has reported accurate and reliable markers to predict pathological response to NAC.
Previously, we had documented in vitro a group of proteins, using two-dimensional gel electrophoresis (2-DE) and MALDI-TOF mass spectrometry, demonstrating differential expression in chemosensitive and chemoresistant MCF-7 breast cancer cell lines.7 These proteins suggested a possible prediction profile in women with breast cancer, who were about to undergo NAC. In the study reported here, five proteins of interest, which are selected based on the results obtained from our previous proteomic studies and hypothesised to be putative biomarkers of prediction of response to chemotherapy, were investigated using immunohistochemical (IHC) staining of pre-treatment core needle biopsies (CNBs) from human breast cancers. These included proteins showing up- or down-regulation, proteins common to the two breast cancer cell lines (resistant to adriamycin and paclitaxel), proteins to which antibodies were commercially available for the research use in human tissues, proteins associated with different functions, as well as proteins that had not previously been documented in published studies. The results of the IHC staining in the pre-treatment tissues were correlated with the pathological response rates obtained after completion of the NAC.
Section snippets
Cell lines and cell clot
The MCF-7 wild type (MCF-7/WT, human breast adenocarcinoma) cell line was purchased from the European Collection of Cell Cultures (ATCC Number HTB-22). The MCF-7 adriamycin-resistant subline (MCF-7/ADR) and the MCF-7 paclitaxel-resistant subline (MCF-7/PAC) were kind gifts from Dr. Timothy Gant (MRC Toxicology Unit, University of Leicester, UK)8 and Dr. Susan Bates (National Cancer Institute, USA),9 respectively. All cell lines were grown, subcultured and tested for resistance to
IHC staining of MCF-7 cell clots
The results of staining of the MCF-7 cell clots are shown in Table 3, and their representative images (20× microscopic examination) are shown in Fig. 1A and B. Annexin-A1, annexin-A2, sorcin and stathmin were found to be over-expressed in chemoresistant MCF-7 cells than in chemosensitive MCF-7 cells. In contrast, HSP27 was found to be under-expressed. These findings were comparable to our previous proteomic study.7
Clinical characteristics versus pathological response and expression of annexins
There was no correlation between the pathological response documented and the
Discussion
Five proteins, significantly over- or under-expressed in our previously reported in vitro study on breast cancer cell lines resistant to chemotherapy, were selected for IHC staining.7 There is an ongoing debate about the reliability of using cancer cell lines as a model for biomolecular cancer research. Breast cancer cell lines have been widely used to investigate various biological mechanisms and signalling pathways, including proliferation, apoptosis, invasion and metastasis of breast cancer
Conflict of interest statement
None declared.
Acknowledgement
This study is funded by the Nottinghamshire-Derbyshire-Lincolnshire Research Alliance, UK.
References (37)
- et al.
Neoadjuvant chemotherapy in women with large and locally advanced breast cancer: chemoresistance and prediction of response to drug therapy
Surgeon
(2006) - et al.
Neoadjuvant treatment for early-stage breast cancer: opportunities to assess tumour response
Lancet Oncol
(2006) - et al.
Increased expression of annexin I and thioredoxin detected by two-dimensional gel electrophoresis of drug resistant human stomach cancer cells
J Biochem Biophys Meth
(1998) - et al.
Annexin-I expression modulates drug resistance in tumor cells
Biochem Biophys Res Commun
(2004) - et al.
Decreased expression of annexin A1 is correlated with breast cancer development and progression as determined by a tissue microarray analysis
Human Pathol
(2006) - et al.
Annexin 1 regulates cell proliferation by disruption of cell morphology and inhibition of cyclin D1 expression through sustained activation of the ERK1/2 MAPK signal
Exp Cell Res
(2003) - et al.
Quantitative proteomics analysis reveals that proteins differentially expressed in chronic pancreatitis are also frequently involved in pancreatic cancer
Mol Cell Proteomics
(2007) - et al.
Angiogenesis-associated protein annexin II in breast cancer: selective expression in invasive breast cancer and contribution to tumor invasion and progression
Exp Mol Pathol
(2006) - et al.
Antibody-directed targeting of angiostatin’s receptor annexin II inhibits Lewis lung carcinoma tumor growth via blocking of plasminogen activation: possible biochemical mechanism of angiostatin’s action
Exp Mol Pathol
(2006) - et al.
Significance of heat shock protein-27 expression in patients with renal cell carcinoma
Urology
(2004)
Can breast cancer Hsp 27 (Heat Shock Protein 27,000) expression influence axillary lymph node status?
Breast
Overexpression of sorcin, a calcium-binding protein, induces a low level of paclitaxel resistance in human ovarian and breast cancer cells
Biochem Pharmacol
Expression of sorcin predicts poor outcome in acute myeloid leukemia
Leukemia Res
Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18
J Clin Oncol
Success of neoadjuvant chemotherapy in conversion of mastectomy to breast conservation surgery
Am Surg
Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer
Brit J Cancer
Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel
J Clin Oncol
Proteomic profiling of MCF-7 breast cancer cells with chemoresistance to different types of anti-cancer drugs
Int J Oncol
Cited by (77)
Circulating tumor cells and coagulation—Minireview
2017, Critical Reviews in Oncology/HematologyIsolation and analysis of differentially expressed genes during ovule abortion in the seedless grape
2016, Scientia HorticulturaeNectin2 influences cell apoptosis by regulating anxa2 expression in neuroblastoma
2023, Acta Biochimica et Biophysica SinicaCopper uptake in adult rainbow trout irradiated during early life stages and in non-irradiated bystander trout which swam with the irradiated fish
2022, International Journal of Radiation Biology